Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Hayes, Benjamin ^a   Briceno, Alya ^a   Asher, Alice ^a   Yu, Michelle ^a   Evans, Jennifer L ^a   Hahn, Judith A ^b   Page, Kimberly ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hepatitis C virus; Injection drug users; Rapid testing

Indexed keywords

ADULT; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMAN; ISOLATION AND PURIFICATION; LABORATORY TEST; MALE; MASS SCREENING; PATIENT ATTITUDE; PATIENT PREFERENCE; PROCEDURES; QUESTIONNAIRE; SUBSTANCE ABUSE; TRANSMISSION; YOUNG ADULT;

ADULT; CLINICAL LABORATORY TECHNIQUES; FEMALE; HEPACIVIRUS; HEPATITIS C; HUMANS; MALE; MASS SCREENING; PATIENT ACCEPTANCE OF HEALTH CARE; PATIENT PREFERENCE; SUBSTANCE ABUSE, INTRAVENOUS; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 84902932346     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-645     Document Type: Article

References (63)

1. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Nelson PK, Mathers BM, Cowie B, Hagan H, Des Jarlais D, Horyniak D, Degenhardt L, Lancet 2011 378 9791 571 583
2. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, Holmberg SD, Ann Intern Med 2014 160 5 293 300
3. Hepatitis C in the United States. Holmberg SD, Spradling PR, Moorman AC, Denniston MM, N Engl J Med 2013 368 20 1859 1861
4. Hepatitis C virus infection in USA: an estimate of true prevalence. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S, Liver Int 2011 31 8 1090 1101
5. Testing for HCV infection: an update of guidance for clinicians and laboratorians. CDC, MMWR Morb Mortal Wkly Rep 2013 62 18 362 365
6. Diagnosis, management, and treatment of hepatitis C: an update. Ghany MG, Strader DB, Thomas DL, Seeff LB, Hepatology 2009 49 4 1335 1374
7. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD, Ann Intern Med 2012 156 4 271 278
8. CDC, Viral Hepatitis Surveillance United States 2010 http://www.cdc.gov/ hepatitis/Statistics/2010Surveillance/PDFs/2010HepSurveillanceRpt.pdf Updated August 20, 2012
9. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, Ouellet LJ, Latka MH, Vlahov D, Strathdee SA, Hudson SM, Kerndt P, Des Jarlais D, Williams IT, Clin Infect Dis 2008 46 12 1852 1858
10. Use of enhanced surveillance for hepatitis C virus infection to detect a cluster among young injection-drug users-New York, November 2004-April 2007. CDC, MMWR Morb Mortal Wkly Rep 2008 57 19 517 521
11. Notes from the field: hepatitis C virus infections among young adults - rural Wisconsin, 2010. CDC, MMWR Morb Mortal Wkly Rep 2012 61 19 358
12. Notes from the field: risk factors for hepatitis C virus infections among young adults-Massachusetts 2010. CDC, MMWR Morb Mortal Wkly Rep 2011 60 42 1457 1458
13. Hepatitis C virus prevention in young persons who inject drugs. US Department of Health and Human Services: Technical Consultation, Office of HIV/AIDS and Infectious Disease Policy Technical consultation 2013 http://aids.gov/pdf/hcv-and-young-pwid-consultation-report.pdf Accessed July 19, 2013
14. Patterns of prescription drug misuse among young injection drug users. Lankenau SE, Teti M, Silva K, Bloom JJ, Harocopos A, Treese M, J Urban Health 2012 89 6 1004 1016
15. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Bruneau J, Roy E, Arruda N, Zang G, Jutras-Aswad D, Addiction 2012 107 7 1318 1327
16. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C, Am J Epidemiol 2008 168 10 1099 1109
17. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR, J Infect Dis 2002 186 11 1558 1564 (Pubitemid 35379631)
18. Hepatitis C virus risk behaviors within the partnerships of young injecting drug users. Hahn JA, Evans JL, Davidson PJ, Lum PJ, Page K, Addiction 2010 105 7 1254 1264
19. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, Alter M, Yartel A, Ward JW, MMWR Recomm Rep 2012 61 RR-4 1 32
20. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Moyer VA, Ann Intern Med 2013 159 5 349 357
21. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E, Am J Public Health 2011 101 11 2151 2155
22. Lack of behavior change after disclosure of hepatitis C virus infection among young injection drug users in Baltimore, Maryland. Ompad DC, Fuller CM, Vlahov D, Thomas D, Strathdee SA, Clin Infect Dis 2002 35 7 783 788
23. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, Kapadia F, Latka MH, Ouellet LJ, Purcell DW, Strathdee SA, Theide H, AIDS 2007 21 14 1923 1932 (Pubitemid 47329769)
24. Risk behaviors after hepatitis C virus seroconversion in young injection drug users in San Francisco. Tsui JI, Vittinghoff E, Hahn JA, Evans JL, Davidson PJ, Page K, Drug Alcohol Depend 2009 105 1-2 160 163
25. Self-reported hepatitis C virus antibody status and risk behavior in young injectors. Hagan H, Campbell J, Thiede H, Strathdee S, Ouellet L, Kapadia F, Hudson S, Garfein RS, Public Health Rep 2006 121 6 710 719 (Pubitemid 46280261)
26. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Kwiatkowski CF, Fortuin Corsi K, Booth RE, Addiction 2002 97 10 1289 1294
27. Serosorting for hepatitis C status in the sharing of injection equipment among Seattle area injection drug users. Burt RD, Thiede H, Hagan H, Drug Alcohol Depend 2009 105 3 215 220
28. Injection behaviors among injection drug users in treatment: the role of hepatitis C awareness. Korthuis PT, Feaster DJ, Gomez ZL, Das M, Tross S, Wiest K, Douaihy A, Mandler RN, Sorensen JL, Colfax G, McCarty D, Cohen SE, Penn PE, Lape D, Metsch LR, Addict Behav 2012 37 4 552 555
29. "To Share or Not to Share?" Serosorting by hepatitis C status in the sharing of drug injection equipment among NHBS-IDU2 participants. Smith BD, Jewett A, Burt RD, Zibbell JE, Yartel AK, Dinenno E, J Infect Dis 2013 208 12 1934 1942
30. Knowledge of status and assessment of personal health consequences with hepatitis C are not enough to change risk behaviour among injecting drug users in Stockholm County, Sweden. Norden L, Saxon L, Kaberg M, Kall K, Franck J, Lidman C, Scand J Infect Dis 2009 41 10 727 734
31. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. CDC, Morb Mortal Wkly Rep 1998 47 (RR-19) 20 21
32. Failure to return for HIV test results among persons at high risk for HIV infection: results from a multistate interview project. Sullivan PS, Lansky A, Drake A, J Acquir Immune Defic Syndr 2004 35 5 511 518 (Pubitemid 38420660)
33. Treatment of acute HCV infection. Grebely J, Matthews G, Dore G, Nat Rev Gastroenterol Hepatol 2011 8 5 265 274
34. Treating hepatitis C virus infection in active substance users. Sylvestre DL, Clin Infect Dis 2005 40 Suppl 5 321 S324
35. Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. Litwin AH, Harris KA Jr, Nahvi S, Zamor PJ, Soloway IJ, Tenore PL, Kaswan D, Gourevitch MN, Arnsten JH, J Subst Abuse Treat 2009 37 1 32 40
36. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. Waizmann M, Ackermann G, J Subst Abuse Treat 2010 38 4 338 345
37. Concurrent group treatment for hepatitis C: implementation and outcomes in a methadone maintenance treatment program. Stein MR, Soloway IJ, Jefferson KS, Roose RJ, Arnsten JH, Litwin AH, J Subst Abuse Treat 2012 43 4 424 432
38. The rapid evolution of treatment strategies for hepatitis C. Muir AJ, Am J Gastroenterol 2014 109 628 635
39. Assessing candidacy for acute hepatitis C treatment among active young injection drug users: a case-series report. Asher A, Lum PJ, Page K, J Assoc Nurses AIDS Care 2012 23 1 16 29
40. Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities. Hagan H, Latka MH, Campbell JV, Golub ET, Garfein RS, Thomas DA, Kapadia F, Strathdee SA, Clin Infect Dis 2006 42 5 669 672 (Pubitemid 43271380)
41. Client satisfaction with rapid HIV testing: comparison between an urban sexually transmitted disease clinic and a community-based testing center. Smith LV, Rudy ET, Javanbakht M, Uniyal A, Sy LS, Horton T, Kerndt PR, AIDS Patient Care STDS 2006 20 10 693 700 (Pubitemid 46141368)
42. Evaluation of youth preferences for rapid and innovative human immunodeficiency virus antibody tests. Peralta L, Constantine N, Griffin Deeds B, Martin L, Ghalib K, Arch Pediatr Adolesc Med 2001 155 7 838 843 (Pubitemid 32613789)
43. Rapid hiv testing in urban outreach: a strategy for improving posttest counseling rates. Keenan PA, Keenan JM, AIDS Educ Prev 2001 13 6 541 550 (Pubitemid 34038706)
44. Acceptability and feasibility of rapid HIV testing in an adolescent clinic setting: youth testing attitudes, knowledge, and behaviors. Tuysuzoglu S, Corliss HL, Fitzgerald SM, Abascal BR, Samples CL, J Adolesc Health 2011 49 6 609 614
45. Choosing HIV counseling and testing strategies for outreach settings: a randomized trial. Spielberg F, Branson BM, Goldbaum GM, Lockhart D, Kurth A, Rossini A, Wood RW, J Acquir Immune Defic Syndr 2005 38 3 348 355 (Pubitemid 40333503)
46. Outcomes of offering rapid point-of-care HIV testing in a sexually transmitted disease clinic. Kendrick SR, Kroc KA, Withum D, Rydman RJ, Branson BM, Weinstein RA, J Acquir Immune Defic Syndr 2005 38 2 142 146 (Pubitemid 40189320)
47. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. Lee SR, Kardos KW, Schiff E, Berne CA, Mounzer K, Banks AT, Tatum HA, Friel TJ, Demicco MP, Lee WM, Eder SE, Monto A, Yearwood GD, Guillon GB, Kurtz LA, Fischl M, Unangst L, Kriebel L, Feiss G, Roehler M, J Virol Methods 2011 172 1-2 27 31
48. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E, Kamili S, Weinbaum CM, J Infect Dis 2011 204 6 825 831
49. Acceptability and implications of rapid HCV test among high risk young injection drug users. Briceno A, Evans J, Hayes B, Hahn J, Page K, Oral presentation at the 2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care Washington, DC 2012
50. Acute hepatitis C virus infection in young adult injection drug users: a prospective study of incident infection, resolution, and reinfection. Page K, Hahn JA, Evans J, Shiboski S, Lum P, Delwart E, Tobler L, Andrews W, Avanesyan L, Cooper S, Busch M, J Infect Dis 2009 200 8 1216 1226
51. Comparison of Hepatitis C Virus RNA and antibody detection in dried blood spots and plasma specimens. Dokubo EK, Evans J, Winkelman V, Cyrus S, Tobler LH, Asher A, Briceno A, Page K, J Clin Virol 2014 59 4 223 227
52. Emergency department patient perceptions and preferences on opt-in rapid HIV screening program components. Merchant RC, Clark MA, Seage GR 3rd, Mayer KH, Degruttola VG, Becker BM, AIDS Care 2009 21 4 490 500
53. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, Monterroso ER, Garfein RS, Am J Epidemiol 2002 155 7 645 653 (Pubitemid 34246097)
54. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman SR, Monterroso E, Williams I, Garfein RS, Am J Epidemiol 2003 157 5 467 471 (Pubitemid 36258602)
55. Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Broz D, Ouellet LJ, Drug Alcohol Depend 2008 94 1-3 221 233
56. SAMHSA, Substance Abuse and Mental Health Services Administration, Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-44, HHS Publication No. (SMA) 12-4713. Rockville, MD 2012 http://www.samhsa.gov/data/NSDUH/2k11Results/ NSDUHresults2011.htm#5.5
57. Association between prescription drug misuse and injection among runaway and homeless youth. Al-Tayyib AA, Rice E, Rhoades H, Riggs P, Drug Alcohol Depend 2014 134 406 409
58. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. Hahn JA, Page-Shafer K, Ford J, Paciorek A, Lum PJ, Drug Alcohol Depend 2008 93 1-2 43 50 (Pubitemid 350236588)
59. Comparison of point-of-care rapid HIV testing in three clinical venues. Kendrick SR, Kroc KA, Couture E, Weinstein RA, AIDS 2004 18 16 2208 2210 (Pubitemid 39463690)
60. Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention. Page K, Morris MD, Hahn JA, Maher L, Prins M, Clin Infect Dis 2013 57 Suppl 2 32 S38
61. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Allen EJ, Palmateer NE, Hutchinson SJ, Cameron S, Goldberg DJ, Taylor A, Int J Drug Policy 2012 23 5 346 352
62. Comparison of hepatitis C virus RNA and antibody detection in dried blood spots and plasma specimens, e-pub ahead of print January 27, 2014. Dokubo EK, Evans J, Winkelman VK, Cyrus S, Asher A, Tobler L, Page K, J Clin Micro 2014 59 4 223 227
63. Detection of hepatitis C virus RNA in dried blood spots. Bennett S, Gunson RN, McAllister GE, Hutchinson SJ, Goldberg DJ, Cameron SO, Carman WF, J Clin Virol 2012 54 2 106 109